{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:11:07Z","timestamp":1793769067535,"version":"4.6.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03574-0","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:36:48Z","timestamp":1758875808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Gut microbiota as a hidden modulator of chemotherapy: implications for colorectal cancer treatment"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4999-5697","authenticated-orcid":false,"given":"Zahra","family":"Sadeghloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"3","key":"3574_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"8","key":"3574_CR2","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386\u2013422.","journal-title":"Ann Oncol"},{"key":"3574_CR3","doi-asserted-by":"publisher","first-page":"356589","DOI":"10.3389\/fmicb.2018.01835","volume":"9","author":"ZY Kho","year":"2018","unstructured":"Kho ZY, Lal SK. The human gut microbiome\u2013a potential controller of wellness and disease. Front Microbiol. 2018;9:356589.","journal-title":"Front Microbiol"},{"issue":"6","key":"3574_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nrgastro.2017.20","volume":"14","author":"JL Alexander","year":"2017","unstructured":"Alexander JL, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Reviews Gastroenterol Hepatol. 2017;14(6):356\u201365.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"6230","key":"3574_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.aaa4972","volume":"348","author":"WS Garrett","year":"2015","unstructured":"Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80\u20136.","journal-title":"Science"},{"issue":"6371","key":"3574_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, et al. Gut Microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"6161","key":"3574_CR7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida N, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967\u201370.","journal-title":"Science"},{"issue":"2","key":"3574_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.chom.2013.07.007","volume":"14","author":"AD Kostic","year":"2013","unstructured":"Kostic AD, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207\u201315.","journal-title":"Cell Host Microbe"},{"issue":"5","key":"3574_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrc.2017.13","volume":"17","author":"S Roy","year":"2017","unstructured":"Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017;17(5):271\u201385.","journal-title":"Nat Rev Cancer"},{"issue":"5728","key":"3574_CR10","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1126\/science.1110591","volume":"308","author":"PB Eckburg","year":"2005","unstructured":"Eckburg PB, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635\u20138.","journal-title":"Science"},{"issue":"11","key":"3574_CR11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/phar.2731","volume":"42","author":"MR Bidell","year":"2022","unstructured":"Bidell MR, Hobbs AL, Lodise TP. Gut Microbiome health and dysbiosis: A clinical primer. Pharmacotherapy: J Hum Pharmacol Drug Therapy. 2022;42(11):849\u201357.","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"issue":"7402","key":"3574_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature11234","volume":"486","author":"H Curtis","year":"2012","unstructured":"Curtis H, et al. Structure, function and diversity of the healthy human Microbiome. Nat (London). 2012;486(7402):207\u201314.","journal-title":"Nat (London)"},{"issue":"6","key":"3574_CR13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","volume":"165","author":"A Koh","year":"2016","unstructured":"Koh A, et al. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332\u201345.","journal-title":"Cell"},{"key":"3574_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00394-017-1445-8","volume":"57","author":"I Rowland","year":"2018","unstructured":"Rowland I, et al. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018;57:1\u201324.","journal-title":"Eur J Nutr"},{"issue":"1","key":"3574_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","volume":"157","author":"Y Belkaid","year":"2014","unstructured":"Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121\u201341.","journal-title":"Cell"},{"issue":"7762","key":"3574_CR16","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","volume":"570","author":"M Zimmermann","year":"2019","unstructured":"Zimmermann M, et al. Mapping human Microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570(7762):462\u20137.","journal-title":"Nature"},{"issue":"10","key":"3574_CR17","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","volume":"33","author":"T Andr\u00e9","year":"2022","unstructured":"Andr\u00e9 T, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from checkmate 142. Ann Oncol. 2022;33(10):1052\u201360.","journal-title":"Ann Oncol"},{"issue":"4","key":"3574_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3322\/caac.21728","volume":"72","author":"F Ciardiello","year":"2022","unstructured":"Ciardiello F, et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. Cancer J Clin. 2022;72(4):372\u2013401.","journal-title":"Cancer J Clin"},{"issue":"9980","key":"3574_CR19","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","volume":"385","author":"LH Simkens","year":"2015","unstructured":"Simkens LH, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch colorectal cancer group. Lancet. 2015;385(9980):1843\u201352.","journal-title":"Lancet"},{"issue":"1","key":"3574_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834015614530","volume":"8","author":"WA Hammond","year":"2016","unstructured":"Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: a review. Therapeutic Adv Med Oncol. 2016;8(1):57\u201384.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"1","key":"3574_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41522-017-0034-1","volume":"3","author":"L Guthrie","year":"2017","unstructured":"Guthrie L, et al. Human Microbiome signatures of differential colorectal cancer drug metabolism. NPJ Biofilms Microbiomes. 2017;3(1):27.","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"5","key":"3574_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330\u20138.","journal-title":"Nat Rev Cancer"},{"key":"3574_CR23","doi-asserted-by":"crossref","unstructured":"Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manage Res, 2011: pp. 79\u201389.","DOI":"10.2147\/CMAR.S11250"},{"key":"3574_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.trsl.2016.08.002","volume":"179","author":"ID Wilson","year":"2017","unstructured":"Wilson ID, Nicholson JK. Gut Microbiome interactions with drug metabolism, efficacy, and toxicity. Translational Res. 2017;179:204\u201322.","journal-title":"Translational Res"},{"issue":"10","key":"3574_CR25","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/s41564-022-01226-5","volume":"7","author":"P Spanogiannopoulos","year":"2022","unstructured":"Spanogiannopoulos P, et al. Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism. Nat Microbiol. 2022;7(10):1605\u201320.","journal-title":"Nat Microbiol"},{"key":"3574_CR26","doi-asserted-by":"publisher","first-page":"100423","DOI":"10.1016\/j.cotox.2023.100423","volume":"36","author":"EKK Lo","year":"2023","unstructured":"Lo EKK, et al. Gut microbiota: impact on 5-fluorouracil efficacy and toxicity. Curr Opin Toxicol. 2023;36:100423.","journal-title":"Curr Opin Toxicol"},{"issue":"3","key":"3574_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2017.03.040","volume":"169","author":"TA Scott","year":"2017","unstructured":"Scott TA, et al. Host-microbe co-metabolism dictates cancer drug efficacy in C. elegans. Cell. 2017;169(3):442\u201356. e18.","journal-title":"Cell"},{"issue":"16","key":"3574_CR28","first-page":"4187","volume":"51","author":"Y Kawato","year":"1991","unstructured":"Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51(16):4187\u201391.","journal-title":"Cancer Res"},{"issue":"4","key":"3574_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discovery. 2005;4(4):307\u201320.","journal-title":"Nat Rev Drug Discovery"},{"issue":"2","key":"3574_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1053\/j.gastro.2022.10.018","volume":"164","author":"D Chrysostomou","year":"2023","unstructured":"Chrysostomou D, et al. Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. Gastroenterology. 2023;164(2):198\u2013213.","journal-title":"Gastroenterology"},{"issue":"1","key":"3574_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-023-01406-7","volume":"8","author":"L-Y Zhao","year":"2023","unstructured":"Zhao L-Y, et al. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. Signal Transduct Target Therapy. 2023;8(1):201.","journal-title":"Signal Transduct Target Therapy"},{"issue":"6005","key":"3574_CR32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1126\/science.1191175","volume":"330","author":"BD Wallace","year":"2010","unstructured":"Wallace BD, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330(6005):831\u20135.","journal-title":"Science"},{"issue":"11","key":"3574_CR33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1080\/17425255.2020.1815705","volume":"16","author":"G Tao","year":"2020","unstructured":"Tao G, et al. Potential role of drug metabolizing enzymes in chemotherapy-induced Gastrointestinal toxicity and hepatotoxicity. Expert Opin Drug Metab Toxicol. 2020;16(11):1109\u201324.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"3574_CR34","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"AB Van Kuilenburg","year":"2004","unstructured":"Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939\u201350.","journal-title":"Eur J Cancer"},{"key":"3574_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40168-018-0483-7","volume":"6","author":"C Panebianco","year":"2018","unstructured":"Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome. 2018;6:1\u201313.","journal-title":"Microbiome"},{"issue":"3","key":"3574_CR36","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","volume":"170","author":"T Yu","year":"2017","unstructured":"Yu T, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548\u201363. e16.","journal-title":"Cell"},{"issue":"3","key":"3574_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.chom.2014.02.007","volume":"15","author":"CL Sears","year":"2014","unstructured":"Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15(3):317\u201328.","journal-title":"Cell Host Microbe"},{"issue":"3","key":"3574_CR38","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ijc.21365","volume":"118","author":"SA Shah","year":"2006","unstructured":"Shah SA, et al. Ursodeoxycholic acid inhibits Interleukin beta 1 and deoxycholic acid-induced activation of NF\u2010\u03baB and AP\u20101 in human colon cancer cells. Int J Cancer. 2006;118(3):532\u20139.","journal-title":"Int J Cancer"},{"issue":"19","key":"3574_CR39","doi-asserted-by":"publisher","first-page":"10209","DOI":"10.3390\/ijms221910209","volume":"22","author":"T-T Nguyen","year":"2021","unstructured":"Nguyen T-T, et al. Lithocholic acid induces miR21, promoting PTEN Inhibition via STAT3 and ERK-1\/2 signaling in colorectal cancer cells. Int J Mol Sci. 2021;22(19):10209.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3574_CR40","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1002\/jcb.25955","volume":"118","author":"TT Nguyen","year":"2017","unstructured":"Nguyen TT, et al. Lithocholic acid stimulates IL-8 expression in human colorectal cancer cells via activation of Erk1\/2 MAPK and suppression of STAT3 activity. J Cell Biochem. 2017;118(9):2958\u201367.","journal-title":"J Cell Biochem"},{"issue":"3","key":"3574_CR41","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10555-023-10117-y","volume":"42","author":"MA Feitelson","year":"2023","unstructured":"Feitelson MA, et al. Short-chain fatty acids in cancer pathogenesis. Cancer Metastasis Rev. 2023;42(3):677\u201398.","journal-title":"Cancer Metastasis Rev"},{"issue":"43","key":"3574_CR42","doi-asserted-by":"publisher","first-page":"27280","DOI":"10.18632\/oncotarget.25546","volume":"9","author":"A Han","year":"2018","unstructured":"Han A, et al. Butyrate decreases its own oxidation in colorectal cancer cells through Inhibition of histone deacetylases. Oncotarget. 2018;9(43):27280.","journal-title":"Oncotarget"},{"issue":"1","key":"3574_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13046-018-0985-y","volume":"38","author":"S Zhang","year":"2019","unstructured":"Zhang S, et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Experimental Clin Cancer Res. 2019;38(1):14.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"1","key":"3574_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12866-023-02791-3","volume":"23","author":"MS Mahdy","year":"2023","unstructured":"Mahdy MS, et al. Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity. BMC Microbiol. 2023;23(1):53.","journal-title":"BMC Microbiol"},{"key":"3574_CR45","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3389\/fmicb.2018.01607","volume":"9","author":"X Deng","year":"2018","unstructured":"Deng X, et al. Comparison of microbiota in patients treated by surgery or chemotherapy by 16S rRNA sequencing reveals potential biomarkers for colorectal cancer therapy. Front Microbiol. 2018;9:1607.","journal-title":"Front Microbiol"},{"issue":"6","key":"3574_CR46","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.chom.2025.05.004","volume":"33","author":"X Ding","year":"2025","unstructured":"Ding X, et al. Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. Cell Host Microbe. 2025;33(6):941\u201356. e10.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"3574_CR47","doi-asserted-by":"publisher","first-page":"2310215","DOI":"10.1080\/19490976.2024.2310215","volume":"16","author":"G Dalmasso","year":"2024","unstructured":"Dalmasso G, et al. Colibactin-producing Escherichia coli enhance resistance to chemotherapeutic drugs by promoting epithelial to mesenchymal transition and cancer stem cell emergence. Gut Microbes. 2024;16(1):2310215.","journal-title":"Gut Microbes"},{"key":"3574_CR48","doi-asserted-by":"publisher","first-page":"1510851","DOI":"10.3389\/fphar.2024.1510851","volume":"15","author":"L Xu","year":"2025","unstructured":"Xu L, et al. Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer. Front Pharmacol. 2025;15:1510851.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3574_CR49","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1038\/s41467-023-40439-y","volume":"14","author":"T Lang","year":"2023","unstructured":"Lang T, et al. Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy. Nat Commun. 2023;14(1):4746.","journal-title":"Nat Commun"},{"key":"3574_CR50","doi-asserted-by":"publisher","first-page":"725583","DOI":"10.3389\/fphar.2021.725583","volume":"12","author":"X Hou","year":"2021","unstructured":"Hou X, et al. Akkermansia muciniphila potentiates the antitumor efficacy of FOLFOX in colon cancer. Front Pharmacol. 2021;12:725583.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3574_CR51","doi-asserted-by":"publisher","first-page":"2186114","DOI":"10.1080\/19490976.2023.2186114","volume":"15","author":"H Xu","year":"2023","unstructured":"Xu H, et al. Therapeutic potential of clostridium Butyricum anticancer effects in colorectal cancer. Gut Microbes. 2023;15(1):2186114.","journal-title":"Gut Microbes"},{"key":"3574_CR52","doi-asserted-by":"publisher","first-page":"1220165","DOI":"10.3389\/fimmu.2023.1220165","volume":"14","author":"X Zhao","year":"2023","unstructured":"Zhao X, et al. Combination of thalidomide and clostridium Butyricum relieves chemotherapy-induced nausea and vomiting via gut microbiota and vagus nerve activity modulation. Front Immunol. 2023;14:1220165.","journal-title":"Front Immunol"},{"issue":"6161","key":"3574_CR53","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud S, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971\u20136.","journal-title":"Science"},{"issue":"4","key":"3574_CR54","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3181\/0810-RM-301","volume":"234","author":"AM Stringer","year":"2009","unstructured":"Stringer AM, et al. Gastrointestinal microflora and mucins May play a critical role in the development of 5-fluorouracil-induced Gastrointestinal mucositis. Experimental Biology Med. 2009;234(4):430\u201341.","journal-title":"Experimental Biology Med"},{"issue":"6","key":"3574_CR55","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.ctim.2013.08.018","volume":"21","author":"M Mego","year":"2013","unstructured":"Mego M, et al. Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy. Complement Ther Med. 2013;21(6):712\u201323.","journal-title":"Complement Ther Med"},{"key":"3574_CR56","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nut.2016.05.003","volume":"33","author":"Y Tang","year":"2017","unstructured":"Tang Y, et al. Administration of probiotic mixture DM# 1 ameliorated 5-fluorouracil\u2013induced intestinal mucositis and dysbiosis in rats. Nutrition. 2017;33:96\u2013104.","journal-title":"Nutrition"},{"issue":"10","key":"3574_CR57","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3390\/jpm13101487","volume":"13","author":"L L\u00f3pez-G\u00f3mez","year":"2023","unstructured":"L\u00f3pez-G\u00f3mez L, Alcorta A, Abalo R. Probiotics and probiotic-like agents against Chemotherapy-Induced intestinal mucositis: a narrative review. J Personalized Med. 2023;13(10):1487.","journal-title":"J Personalized Med"},{"issue":"9","key":"3574_CR58","doi-asserted-by":"publisher","first-page":"e0138746","DOI":"10.1371\/journal.pone.0138746","volume":"10","author":"C-Y Yeung","year":"2015","unstructured":"Yeung C-Y, et al. Amelioration of chemotherapy-induced intestinal mucositis by orally administered probiotics in a mouse model. PLoS ONE. 2015;10(9):e0138746.","journal-title":"PLoS ONE"},{"key":"3574_CR59","doi-asserted-by":"publisher","first-page":"823288","DOI":"10.3389\/fnut.2022.823288","volume":"9","author":"J Feng","year":"2022","unstructured":"Feng J, et al. Oral administration of probiotics reduces chemotherapy-induced diarrhea and oral mucositis: a systematic review and meta-analysis. Front Nutr. 2022;9:823288.","journal-title":"Front Nutr"},{"issue":"5","key":"3574_CR60","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrgastro.2015.47","volume":"12","author":"LB Bindels","year":"2015","unstructured":"Bindels LB, et al. Towards a more comprehensive concept for prebiotics. Nat Reviews Gastroenterol Hepatol. 2015;12(5):303\u201310.","journal-title":"Nat Reviews Gastroenterol Hepatol"},{"issue":"8","key":"3574_CR61","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/ijc.32003","volume":"145","author":"D Chen","year":"2019","unstructured":"Chen D, et al. Fecal microbiota transplantation in cancer management: current status and perspectives. Int J Cancer. 2019;145(8):2021\u201331.","journal-title":"Int J Cancer"},{"issue":"6371","key":"3574_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, et al. Gut Microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"key":"3574_CR63","doi-asserted-by":"publisher","first-page":"781697","DOI":"10.3389\/fonc.2021.781697","volume":"11","author":"N Li","year":"2021","unstructured":"Li N, et al. The relationship between gut Microbiome features and chemotherapy response in Gastrointestinal cancer. Front Oncol. 2021;11:781697.","journal-title":"Front Oncol"},{"issue":"10","key":"3574_CR64","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.chom.2021.08.001","volume":"29","author":"A Montalban-Arques","year":"2021","unstructured":"Montalban-Arques A, et al. Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe. 2021;29(10):1573\u201388. e7.","journal-title":"Cell Host Microbe"},{"issue":"5","key":"3574_CR65","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/apt.13302","volume":"42","author":"E Montassier","year":"2015","unstructured":"Montassier E, et al. Chemotherapy-driven dysbiosis in the intestinal Microbiome. Aliment Pharmacol Ther. 2015;42(5):515\u201328.","journal-title":"Aliment Pharmacol Ther"},{"key":"3574_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-019-1047-4","volume":"19","author":"L Zaharuddin","year":"2019","unstructured":"Zaharuddin L, et al. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019;19:1\u20138.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"3574_CR67","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1136\/gutjnl-2021-326264","volume":"71","author":"NL-N Ting","year":"2022","unstructured":"Ting NL-N, Lau HC-H, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut. 2022;71(7):1412\u201325.","journal-title":"Gut"},{"issue":"12","key":"3574_CR68","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41591-018-0238-9","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24(12):1804\u20138.","journal-title":"Nat Med"},{"issue":"10","key":"3574_CR69","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.ccell.2021.08.006","volume":"39","author":"N Cullin","year":"2021","unstructured":"Cullin N, et al. Microbiome and cancer. Cancer Cell. 2021;39(10):1317\u201341.","journal-title":"Cancer Cell"},{"issue":"26","key":"3574_CR70","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1038\/s41388-020-1341-1","volume":"39","author":"W Fong","year":"2020","unstructured":"Fong W, Li Q, Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene. 2020;39(26):4925\u201343.","journal-title":"Oncogene"},{"key":"3574_CR71","doi-asserted-by":"crossref","unstructured":"Yao B, Wei W, Zhang H. Efficacy of probiotics or synbiotics supplementation on chemotherapy-induced complications and gut microbiota dysbiosis in Gastrointestinal cancer: a systematic review and meta-analysis. Eur J Clin Nutr, 2024: pp. 1\u201311.","DOI":"10.1038\/s41430-024-01542-5"},{"issue":"3","key":"3574_CR72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3892\/ijo.2021.5255","volume":"59","author":"S Vivarelli","year":"2021","unstructured":"Vivarelli S, et al. Novel insights on gut microbiota manipulation and immune checkpoint Inhibition in cancer. Int J Oncol. 2021;59(3):75.","journal-title":"Int J Oncol"},{"issue":"7","key":"3574_CR73","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tim.2017.11.002","volume":"26","author":"A Heintz-Buschart","year":"2018","unstructured":"Heintz-Buschart A, Wilmes P. Human gut microbiome: function matters. Trends Microbiol. 2018;26(7):563\u201374.","journal-title":"Trends Microbiol"},{"issue":"12","key":"3574_CR74","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/nutrit\/nux062","volume":"75","author":"GR Healey","year":"2017","unstructured":"Healey GR, et al. Interindividual variability in gut microbiota and host response to dietary interventions. Nutr Rev. 2017;75(12):1059\u201380.","journal-title":"Nutr Rev"},{"issue":"2","key":"3574_CR75","doi-asserted-by":"publisher","first-page":"e00060","DOI":"10.1128\/cmr.00060-22","volume":"37","author":"A Yadegar","year":"2024","unstructured":"Yadegar A, et al. Fecal microbiota transplantation: current challenges and future landscapes. Clin Microbiol Rev. 2024;37(2):e00060\u201322.","journal-title":"Clin Microbiol Rev"},{"issue":"21","key":"3574_CR76","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","volume":"381","author":"Z DeFilipp","year":"2019","unstructured":"DeFilipp Z, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381(21):2043\u201350.","journal-title":"N Engl J Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03574-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03574-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03574-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:03:16Z","timestamp":1758880996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03574-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3574"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03574-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1717"}}